Table 3 Costs and cost-effectiveness of the use of WES at three points in the diagnostic trajectory compared with standard diagnostic care

From: Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement